Search

Your search keyword '"Reyes-Maldonado, E."' showing total 3 results
Start Over Author "Reyes-Maldonado, E." Journal stem cells and development
3 results on '"Reyes-Maldonado, E."'

1. CD4+CD25+Lymphocyte and Dendritic Cell Mobilization with Intermediate Doses of Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Donors

Author

Vela-Ojeda, J., primary, Esparza, M.A. García-Ruiz, additional, Reyes-Maldonado, E., additional, Jiménez-Zamudio, L., additional, García-Latorre, E., additional, Moreno-Lafont, M., additional, Estrada-García, I., additional, Mayani, H., additional, Montiel-Cervantes, L., additional, Tripp-Villanueva, F., additional, Ayala-Sánchez, M., additional, García-León, L.D., additional, and Borbolla-Escoboza, J.R., additional

Published
2005
Full Text
View/download PDF

2. CD4+ CD25+ Lymphocyte and Dendritic Cell Mobilization with Intermediate Doses of Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Donors

Author

Vela-Ojeda, J., Esparza, M.A. García-Ruiz, Reyes-Maldonado, E., Jiménez-Zamudio, L., García-Latorre, E., Moreno-Lafont, M., Estrada-García, I., Mayani, H., Montiel-Cervantes, L., Tripp-Villanueva, F., Ayala-Sánchez, M., García-León, L.D., and Borbolla-Escoboza, J.R.

Abstract

We prospectively conducted a quantitative and phenotypic analysis of T, B, natural killer (NK), NKT, type 1 and 2 dendritic cells (DC), and regulatory T cells, before and after mobilization with intermediate doses of granulocyte colony-stimulating factor (G-CSF) (16 µg/kg per day). Between November, 2003, and December, 2004, we collected stem cells from 25 HLA identical sibling donors for allogeneic hematopoietic stem cell transplantation. Before mobilization and 3 h after the fourth and fifth doses of G-CSF, blood samples were taken for blood counts and flow cytometry. The median number of regulatory T cells before and after G-CSF was statistically different (69 ± 41 × 106/L versus 161 ± 159 × 106/L, p < 0.01). We observed a 1.7-fold increase in NK and NKT cells (p < 0.009 and p < 0.02, respectively). DC were mobilized with a 11.5-fold increase in type 2 (p < 0.004) and a 8.5-fold increase in type 1 DC (p < 0.003). The patients received a mean of: 2.2 × 107/kg ± 1.4 × 107/kg of NK cells, 0.95 × 107/kg ± 0.81 × 107/kg of NKT cells, 0.43 × 107/kg ± 0.53 × 107/kg of type 1 DC, 0.3 v 107/kg ± 0.45 × 107/kg of type 2 DC and 1.4 × 107/kg ± 1.2 × 107/kg of regulatory T cells. Using intermediate doses of G-CSF, we have demonstrated the mobilization of different lymphocyte subsets, in particular regulatory T cells and DC, which can be expanded later and used in the treatment of cancer and autoimmune diseases.

Published
2005
Full Text
View/download PDF

3. Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation.

Author

Vela-Ojeda J, Montiel-Cervantes L, Granados-Lara P, Reyes-Maldonado E, García-Latorre E, Garcia-Chavez J, Majluf-Cruz A, Mayani H, Borbolla-Escoboza JR, and Esparza MG

Subjects
Female, Flow Cytometry, Forkhead Transcription Factors immunology, Graft Survival immunology, Graft vs Host Disease etiology, Granulocyte Colony-Stimulating Factor pharmacology, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Interleukin-2 Receptor alpha Subunit immunology, Killer Cells, Natural cytology, Killer Cells, Natural drug effects, L-Selectin immunology, Male, Survival Analysis, T-Lymphocytes, Regulatory cytology, T-Lymphocytes, Regulatory drug effects, Time Factors, Transplantation Conditioning methods, Transplantation, Homologous, Graft vs Host Disease immunology, Hematopoietic Stem Cell Transplantation methods, Killer Cells, Natural immunology, T-Lymphocytes, Regulatory immunology
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for some hematological diseases; however, graft-versus-host disease (GVHD) is still one of the most important and deleterious complications. Regulatory T cells and iNKT cells can decrease the incidence and severity of GVHD, while preserving the graft-versus-tumor response. In order to analyze the relationship between the transfused dose of these cells, the presence of GVHD and survival, 15 normal donors and 15 patients with hematological diseases who underwent allogeneic HSCT from HLA-identical siblings were studied. The mobilization and infused doses of valpha24-vbeta11(iNKT cells) lymphocytes and CD4+CD25+FoxP3+, CD4+CD25+FoxP3+CD62L+, regulatory T cells were analyzed. All patients were conditioned with busulfan and cyclophosphamide and received cyclosporine and methotrexate as GVHD prophylaxis. iNKT and FoxP3 cells were mobilized after G-CSF administration. Acute GVHD was present in 9 of 15 (60%) and cGVHD in 7 of 13 (54%) patients. Patients who received a dose <0.6 x 10(6)/kg of iNKT cells and >4 x 10(6)/kg of FoxP3 had better disease-free survival and overall survival. Individuals transfused with >1.1 x 10(6)/kg of FoxP3+ CD62L+ Treg cells had better overall survival. In conclusion, iNKT and Treg cells are mobilized with G-CSF in healthy donors and the dose of iNKT cells and FoxP3 and CD62L+ regulatory T cells is of clinical importance in human HSCT.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results